Sharon Elad1, Reuven Or, Adi A Garfunkel, Michael Y Shapira. 1. Hospital Oral Medicine Department, Hadassah University Hospital and The Hebrew University-Hadassah School Of Dental Medicine, Jerusalem, Israel. eladhome@md.huji.ac.il
Abstract
OBJECTIVE: This clinical trial aims to evaluate the efficacy of budesonide, a newly registered steroid with high potency and low bioavailability, for the treatment of chronic oral graft versus host disease (GVHD). STUDY DESIGN: Twelve patients with chronic resistant oral GVHD were treated with 3 mg budesonide/5 ml saline 2 to 3 times a day for up to 3 months. Oral manifestations were monitored, and mucosal response scored. RESULTS: All patients responded positively to the mouthwash, and 7 of the 12 patients were scored as having "good" or "complete" recovery by both examiner and subject. An early response noted within the first 2 to 3 weeks of treatment was complemented by a probable cumulative effect seen during the first months of treatment. CONCLUSION: Budesonide is suggested as an alternative treatment for chronic oral GVHD.
OBJECTIVE: This clinical trial aims to evaluate the efficacy of budesonide, a newly registered steroid with high potency and low bioavailability, for the treatment of chronic oral graft versus host disease (GVHD). STUDY DESIGN: Twelve patients with chronic resistant oral GVHD were treated with 3 mg budesonide/5 ml saline 2 to 3 times a day for up to 3 months. Oral manifestations were monitored, and mucosal response scored. RESULTS: All patients responded positively to the mouthwash, and 7 of the 12 patients were scored as having "good" or "complete" recovery by both examiner and subject. An early response noted within the first 2 to 3 weeks of treatment was complemented by a probable cumulative effect seen during the first months of treatment. CONCLUSION:Budesonide is suggested as an alternative treatment for chronic oral GVHD.
Authors: Rami B Ibrahim; Muneer H Abidi; Simon M Cronin; Lawrence G Lum; Zaid Al-Kadhimi; Voravit Ratanatharathorn; Joseph P Uberti Journal: Biol Blood Marrow Transplant Date: 2009-02-10 Impact factor: 5.742
Authors: Rui Albuquerque; Zahid Khan; Ana Poveda; Jonathan Higham; Andrea Richards; Luis Monteiro; Enric Jané-Salas; José Lopez-Lopez; Saman Warnakulasuriya Journal: Med Oral Patol Oral Cir Bucal Date: 2016-01-01